130 related articles for article (PubMed ID: 30848576)
1. The Anti-tumoral Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID on Treg Cells Frequency and MMP-2, MMP-9, CCL22 and TGFβ1 Gene Expression in Pre-surgical Breast Cancer Patients.
Kashefi S; Ahmadi H; Omranipour R; Mahmoodzadeh H; Jafarnezhad-Ansariha F; Tofighi Zavareh F; Mirshafiey A
Iran J Allergy Asthma Immunol; 2019 Feb; 18(1):80-90. PubMed ID: 30848576
[TBL] [Abstract][Full Text] [Related]
2. The Oral Administration Effect of Drug Mannuronic Acid (M2000) on Gene Expression of Matrix and Tissue Inhibitor of Metalloproteinases in Rheumatoid Arthritis Patients.
Gaafar NAG; Aslani M; Aghazadeh Z; Razavi A; Mirshafiey A
Curr Drug Discov Technol; 2020; 17(5):704-710. PubMed ID: 31250758
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory Property of β-D-Mannuronic Acid (M2000) on Expression and Activity of Matrix Metalloproteinase-2 and -9 through CD147 Molecule in Phorbol Myristate Acetate-differentiated THP-1 Cells.
M Farahani M; Motevaseli E; Maghsood F; Heidari-Kharaji M; Mirshafiey A
Iran J Allergy Asthma Immunol; 2017 Oct; 16(5):443-451. PubMed ID: 29149784
[TBL] [Abstract][Full Text] [Related]
4. The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.
Jafarnezhad-Ansariha F; Yekaninejad MS; Jamshidi AR; Mansouri R; Vojdanian M; Mahmoudi M; Fattahi MJ; Hashemi SN; Rehm BHA; Matsuo H; Esposito E; Cuzzocrea S; Mirshafiey A
Inflammopharmacology; 2018 Apr; 26(2):375-384. PubMed ID: 28819782
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenesis effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model.
Rastegari-Pouyani M; Mostafaie A; Mansouri K; Mortazavi-Jahromi SS; Mohammadi-Motlagh HR; Mirshafiey A
Clin Exp Pharmacol Physiol; 2018 Apr; 45(4):370-376. PubMed ID: 29266560
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions.
Mortazavi-Jahromi SS; Jamshidi MM; Farazmand A; Aghazadeh Z; Yousefi M; Mirshafiey A
Pharmacol Rep; 2017 Jun; 69(3):479-484. PubMed ID: 28324845
[TBL] [Abstract][Full Text] [Related]
7. Targeting of crosstalk between tumor and tumor microenvironment by β-D mannuronic acid (M2000) in murine breast cancer model.
Hosseini F; Hassannia H; Mahdian-Shakib A; Jadidi-Niaragh F; Enderami SE; Fattahi M; Anissian A; Mirshafiey A; Kokhaei P
Cancer Med; 2017 Mar; 6(3):640-650. PubMed ID: 28211615
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor effect of M2000 (β-d-mannuronic acid) on the expression of inflammatory molecules in the prostate cancer cell.
Mohsenzadegan M; Moghbeli F; Mirshafiey A; Farajollahi MM
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):419-430. PubMed ID: 34057866
[No Abstract] [Full Text] [Related]
9. Efficacy of β-D-Mannuronic Acid [M2000] on the Pro-Apoptotic Process and Inflammatory-Related Molecules NFκB, IL-8 and Cd49d using Healthy Donor PBMC.
Khalatbari A; Mahdavi M; Jafarnezhad F; Afraei S; Zavareh FT; Aghazadeh Z; Ghaderi A; Mirshafiey A
Curr Drug Discov Technol; 2020; 17(2):225-232. PubMed ID: 30417790
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approach by a novel designed anti-inflammatory drug, M2000, in experimental immune complex glomerulonephritis.
Mirshafiey A; Rehm B; Sotoude M; Razavi A; Abhari RS; Borzooy Z
Immunopharmacol Immunotoxicol; 2007; 29(1):49-61. PubMed ID: 17464766
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled, phase II clinical trial of β-D-mannuronic acid (M2000) in pre-surgical breast cancer patients at early stage (T1-T2).
Kashefi S; Omranipour R; Mahmoodzadeh H; Ahmadi H; Alikhassi A; Hosseini M; Cuzzocrea S; Rehm BHA; Matsuo H; Mirshafiey A
Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):527-532. PubMed ID: 30887570
[TBL] [Abstract][Full Text] [Related]
12. Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis.
Fattahi MJ; Ahmadi H; Jafarnezhad-Ansariha F; Mortazavi-Jahromi SS; Rehm BHA; Cuzzocrea S; Matsuo H; Mirshafiey A
Biomed Pharmacother; 2018 Apr; 100():495-500. PubMed ID: 29477913
[TBL] [Abstract][Full Text] [Related]
13. Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression.
Mirshafiey A; Taeb M; Mortazavi-Jahromi SS; Jafarnezhad-Ansariha F; Rehm BHA; Esposito E; Cuzzocrea S; Matsuo H
Pharmacol Rep; 2017 Oct; 69(5):1067-1072. PubMed ID: 28951072
[TBL] [Abstract][Full Text] [Related]
14. Hematological Improvement of Patients with Active Rheumatoid Arthritis by β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property.
Ahmadi H; Jamshidi AR; Mahmoudi M; Gharibdoost F; Vojdanian M; Fattahi MJ; Rastkari N; Aghazadeh Z; Mirshafiey A
Iran J Allergy Asthma Immunol; 2017 Oct; 16(5):433-442. PubMed ID: 29149783
[TBL] [Abstract][Full Text] [Related]
15. Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug.
Mirshafiey A; Cuzzocrea S; Rehm B; Mazzon E; Saadat F; Sotoude M
Scand J Immunol; 2005 May; 61(5):435-41. PubMed ID: 15882435
[TBL] [Abstract][Full Text] [Related]
16. Anti-aging effects of M2000 (β-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model.
Hosseini S; Abdollahi M; Azizi G; Fattahi MJ; Rastkari N; Zavareh FT; Aghazadeh Z; Mirshafiey A
J Basic Clin Physiol Pharmacol; 2017 May; 28(3):249-255. PubMed ID: 28207414
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotective effect of β-d-mannuronic acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model.
Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):284-289. PubMed ID: 29619884
[TBL] [Abstract][Full Text] [Related]
18. The Biology of β-D-mannuronic acid (M2000) on Human Dendritic Cell Based on MicroRNA-155 and MicroRNA-221.
Tabrizian N; Fard NA; Farazmand A; Eftekhari R; Zavareh FT; Mirshafiey A
Curr Drug Discov Technol; 2017; 14(1):53-58. PubMed ID: 27890012
[TBL] [Abstract][Full Text] [Related]
19. An in vitro assessment for evaluating the efficiency of β-d-mannuronic acid (M2000) in myelodysplastic syndrome.
Bakhtiari T; Ghaderi A; Safaee Nodehi SR; Aghazadeh Z; Tofighi Zavareh F; Jafarnezhad-Ansariha F; Barati A; Mirshafiey A
J Cell Physiol; 2019 Aug; 234(8):12971-12977. PubMed ID: 30537258
[TBL] [Abstract][Full Text] [Related]
20. The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis.
Ahmadi H; Jamshidi AR; Mahmoudi M; Cuzzocrea S; Fattahi MJ; Barati A; Rehm BHA; Matsuo H; Mirshafiey A
Curr Drug Discov Technol; 2017; 14(3):206-214. PubMed ID: 28325148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
